Active Headache & Migraine Studies

We are constantly seeking participants for a number of studies. Please apply to any studies for which you may qualify, or call us at (417) 883-7889 for more information!

If You Suffer from Migraines, Clinvest Is Here to Help

The piercing sensation from a headache or migraine can be debilitating. Our goal is to research and collect data on new medications that may be life-changing to this painful condition. We conduct a variety of headache and migraine studies with specific study topics ranging from chronic migraine prevention to post-traumatic headaches.

Clinvest knows how challenging and frustrating head pain can be. We have a strong commitment to further treatment and research in migraine studies. We partner with pharmaceutical companies in an effort to discover solutions for such debilitating conditions and look forward to the new horizons in health and well-being.

    Migraine Research Study

    3101-301-002

    Dr. True and Clinvest are seeking volunteers with Episodic Migraines in the Springfield area. The purpose of this research study is to evaluate the safety and efficacy of the investigational drug, Atogepant. Qualified volunteers, who have previously taken an oral migraine preventative medication, will be randomly assigned to receive investigational drug or Placebo. Completion of the study would involve coming into the office for 8 appointments over a 16-week period. Your first appointment will last approximately 2 hours. You will be asked to come into the office 4 weeks following screening and every 2 weeks for the duration of the 16-week study. A safety follow-up visit will occur 4 weeks after your last dose. At the completion of the study, participants will have the option to continue in a 40 week Open-Label study where active medication will be provided.

    Duration: 20 Weeks

    Number: 8

    Migraine Research Study

    MOMENTUM

    Eligible subjects ages 18-65 will come to our office for 3 visits over 13 weeks and treat one migraine attack at home with investigational product. Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide an investigational study pill and all study-related procedures at no cost to you (including basic study-related physical exams, bloodwork, ECG’s, and urine drug/pregnancy tests). You will be asked to complete a detailed diary about your treated migraine attack. Compensation will be provided for your time and travel.

    Duration: Up to 13 Weeks

    Number: 3

    Migraine Study

    GM-US-10

    This study consists of 5 in-person visits and 1 phone call over 16 weeks. Qualified people who report 8-20 headaches per month will be randomized to use non-invasive vagus nerve stimulation delivered through an investigational device 3 times a day during a 12-week treatment phase.  Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide the study device and all study-related procedures at no cost to you. You would be asked to use an electronic diary to answer daily questions about your headaches for the entire duration of the study. You would also be asked to fill out more detailed questionnaires during the appointments. Compensation will be provided for your time and travel.

    Duration: 16 Weeks

    Number: 5

    Post Traumatic Headaches

    TV48125-CNS-20024

    This research study is to compare the duration, safety, and effectiveness of the investigational study medication (Fremanezumab) to placebo (an inactive look-alike). Qualified volunteers will be randomly assigned to receive study medication or placebo. Completion of the study would involve coming to our office for 7 appointments, over a 44-week period. Subjects will receive 3 doses of investigational product or placebo during the study.

    Duration: 32 Weeks

    Number: 8

    Chronic Migraine Prevention

    .

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine.

    Duration: 20 Weeks

    Number: 16

Want to find out when new studies are available?

Fill out the form!